Exp Clin Endocrinol Diabetes 2010; 118(2): 93-95
DOI: 10.1055/s-0029-1241198
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Functional Analysis of the Common Haplotype in the Receptor for Advanced Glycation End-Products Gene Previously Identified as a Susceptibility Factor for Diabetic Nephropathy

K. Kankova1 , P. Benes2 , S. Kuchrickova1
  • 1Masaryk University, Dept. of Pathophysiology, Faculty of Medicine, Brno, Czech Republic
  • 2Masaryk University, Dept. of Experimental Biology, Faculty of Science, Brno, Czech Republic
Further Information

Publication History

received 03.06.2009 first decision 27.08.2009

accepted 09.09.2009

Publication Date:
28 January 2010 (online)

Abstract

The Receptor for Advanced Glycation End-products (RAGE) belongs to the family of pattern-recognition receptors and is significantly involved in the molecular mechanisms mediating pro-inflammatory action of hyperglycemia in diabetes. The aim of the current study was to elucidate the possible functional impact of the genetic variability in the AGER gene constituting previously identified risk haplotype for diabetic nephropathy (−429C/-374T/2184G) by testing the haplotype-specific effect on the AGER gene transcriptional activity in vitro. Promotor and intron 8 constructs carrying respective substitutions were amplified and cloned into pGL3-Basic reporter vector and subsequently used for transfection of HEK293 cells. Following 48hrs incubation in either normo- (5 mM/L) or hyperglycemic (25 mM/L) culture medium luciferase activity was measured to assess transcriptional efficiency. Risk haplotype was associated with the highest transcriptional activity in hyperglycemia and greatest relative increase of activity between normo- and hyperglycemia conditions (approx. 3-times). We conclude that ascertained functional differences in the regulatory regions of the AGER gene might have significant consequences for the development of hyperglycemia-related pathology in diabetics.

References

  • 1 Yan SF, Du Yan S, Ramasamy R. et al . Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation.  Ann Med. 2009;  1-15
  • 2 Kankova K, Zahejsky J, Marova I. et al . Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM.  J Diabetes Complications. 2001;  15 185-192
  • 3 Kankova K, Stejskalova A, Hertlova M. et al . Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus.  Nephrol Dial Transplant. 2005;  20 1093-1102
  • 4 Kankova K, Stejskalova A, Pacal L. et al . Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach.  Diabetologia. 2007;  50 990-999
  • 5 Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.  J Biol Chem. 1997;  272 16498-16506
  • 6 Hudson BI, Stickland MH, Futers TS. et al . Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.  Diabetes. 2001;  50 1505-1511
  • 7 Wang Z, Burge CB. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code.  RNA. 2008;  14 802-813
  • 8 Ying SY, Lin SL. Intron-mediated RNA interference and microRNA biogenesis.  Methods Mol Biol. 2009;  487 387-413
  • 9 Kanková K, Kalousová M, Hertlová M. et al . Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene.  Arch Physiol Biochem. 2008;  114 111-119

Correspondence

Dr. K. Kankova

Masaryk University

Dept. of Pathophysiology

UKB Kamenice 5-A18

625 00 Brno

Czech Republic

Phone: +420 549 494 525

Fax: +420 549 494 340▪

Email: kankov@med.muni.cz

    >